R

Repare Therapeutics Inc. (RPTX)

NMS – Real Time Price. Currency in USD

2.65

0.00 (0.00%)

At close: Jan 27, 2026, 4:00 PM EDT

Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Repare Therapeutics Inc. (RPTX)

NMS – Real Time Price. Currency in USD

2.65

0.00 (0.00%)

At close: Jan 27, 2026, 4:00 PM EDT

16.01.2026

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly “Xeno”) a non-profit biotechnology company, b.

24.12.2025

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”). “We are pleased to announce this transaction which combines Gilead's leading expertise in oncology research and development with RP-3467, a potential best-in-class.

20.11.2025

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that following the announcement on November 14, 2025 of the entering into of a definitive arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, “Xeno”), a non-profit biotechnology company, pursuant to which Xeno will acquire (the “Transaction”) all of the issued and outstanding common shar.

18.11.2025

Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights

17.11.2025

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Repare Therapeutics Inc. (NASDAQ: RPTX)

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Repare Therapeutics Inc. (NASDAQ: RPTX ) related to its sale to XenoTherapeutics, Inc. Upon closing of the proposed transaction, it is estimated that each Repare shareholder will receive a cash payment of $1.82 per share, plus one non-transferable contingent value right entitling the holder to receive certain cash payments under certain conditions. Is it a fair deal?

17.11.2025

Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value

XenoTherapeutics Inc. and Xeno Acquisition Corp, a non-profit biotechnology company, on Friday agreed to acquire Repare Therapeutics Inc. (NASDAQ: RPTX).

15.11.2025

RPTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Repare Therapeutics Inc. is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Repare Therapeutics Inc. (NASDAQ: RPTX) to XenoTherapeutics, Inc. is fair to Repare shareholders. Upon closing of the proposed transaction, it is estimated that each Repare shareholder will receive a cash payment of $1.82 per share, plus one non-transferable contingent value right entitling the holder to receive certain cash payments under certain conditions. Halper Sadeh encourages Re.

Videos

No Data

There is no data to display

Press releases

16.01.2026

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that its Shareholders (as defined below) have approved the acquisition of all of the issued and outstanding common shares of the Company (the “Common Shares” and the holders of the Common Shares, the “Shareholders”) by XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly “Xeno”) a non-profit biotechnology company, b.

24.12.2025

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's polymerase theta (Polθ) ATPase inhibitor, RP-3467 (the “Gilead Agreement”). “We are pleased to announce this transaction which combines Gilead's leading expertise in oncology research and development with RP-3467, a potential best-in-class.

20.11.2025

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced that following the announcement on November 14, 2025 of the entering into of a definitive arrangement agreement with XenoTherapeutics, Inc. and Xeno Acquisition Corp. (jointly, “Xeno”), a non-profit biotechnology company, pursuant to which Xeno will acquire (the “Transaction”) all of the issued and outstanding common shar.

18.11.2025

Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights Shareholders should contact the firm immediately as there may be limited time to enforce your rights

Repare Therapeutics Inc. (RPTX)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Repare Therapeutics Inc. (RPTX)

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Repare Therapeutics Inc. (NASDAQ: RPTX)

Repare Therapeutics Agrees To Acquisition As Board Cites Best Path For Stakeholder Value

RPTX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Repare Therapeutics Inc. is Fair to Shareholders

Videos

No Data

Press releases

Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.

Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration

Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.

Halper Sadeh LLC Encourages RPTX and SEE Shareholders to Contact the Firm to Discuss Their Rights